Choisissez votre pays / Select your country

Ninalia NIPT The prenatal trisomy screening test based on maternal blood sample

Support during your pregnancy

According to your medical record for the management of your pregnancy, you might undergo a wide range of tests.

Non-invasive sample
  • Ultrasound
  • Maternal Serum Markers (MSM)
  • Non-Invasive Prenatal Testing (NIPT)
Invasive sample
  • Amniocentesis
  • Chorionic villus sampling

One of these test, the combined screening for trisomy 21 is designed to screen for the risk of trisomy 21 in the unborn child.
This risk is calculated on the basis of three elements:

  • the woman’s age,
  • the ultrasound,
  • a blood sample for assaying the serum markers (blood proteins) in the pregnant woman.

The result of this test is expressed as a “low risk” or “high risk” of the foetus being affected by trisomy 21 with a detection rate of around 85%.

A risk indicated by the maternal serum markers (MSMs) does not mean that the foetus is affected by a chromosome anomaly. A foetal karotype can be performed to confirm or disprove this result. This test analyses an invasively obtained sample of the unborn child’s chromosomes (by amniocentesis or chorionic villus sampling).

Can invasive testing be avoided with NIPT?

Non-Invasive Prenatal Testing is an alternative offered to pregnant women at risk of foetal trisomy before resorting to invasive sampling. On the basis of the results, NIPT can be used to determine whether an amniocentesis (or other invasive action) is indicated.


The NIPT generates two kinds of result:

  • A positive result: there is a high risk that the foetus is affected by one of the suspected anomalies (trisomies 13, 18 and 21). In this case, NIPT as a screening test is not by itself adequate for the creation of a diagnosis. A foetal karotype test on an invasive sample is indicated to confirm the result..
  • A negative result: the risk is extremely low. In this case, an invasive sample is not recommended and your pregnancy can proceed under medical supervision and with “conventional” ultrasound.
  • Autosomal aneuploidies and chromosomal imbalance are rare chromosomal abnormalites. In case of positive result, your healthcare professional will explain to you the care best suited to you.

The benefit of using the Ninalia NIPT in monitoring pregnancies of women at risk

In many cases, NIPT means that invasive sampling can be dispensed with, thus reducing the associated risk of losing the foetus.*

Ninalia NIPT by Eurofins Biomnis is reliable, rapid and high performance (detection rate >99,9 % for trisomies 21, 18 and 13).

Unlike other tests available on the market, Ninalia NIPT performed at Eurofins Biomnis provides primary screening for women expecting twins (screening by blood markers is not currently recommended for pregnancies with twins).

* Non-invasive prenatal testing of trisomies 13, 18 and 21 could make 95% of invasive tests, with an associated risk of miscarriage of around 0.5 to 1%, redundant (source: French National College of Gynaecologists and Obstetricians (CNGOF).

Support during your pregnancy Support during your pregnancy

Vous avez refusé de partager votre position.
Désolé. Nous n'arrivons pas à savoir où vous êtes...
Il faut nous autoriser à voir votre position...
Votre navigateur ne possède pas cette fonctionnalité.

Partner laboratories

out of laboratories in total out of laboratories in total